Acute tubular necrosis (ATN) is the most common cause of intrinsic renal acute kidney injury, resulting from ischemic or toxic injury to proximal and thick ascending limb tubular epithelium. Ischemia from prolonged hypotension or sepsis causes cellular ATP depletion, loss of ion gradients, and apoptosis/necrosis. Nephrotoxins (aminoglycosides, contrast, myoglobin) directly damage tubular cells. The initial insult is followed by a recovery phase where surviving tubular cells regenerate and dedifferentiate, restoring renal function over days to weeks. ATN causes muddy brown casts and epithelial cell casts in urine.
Distinguish ischemic ATN (from sepsis, cardiogenic shock) from nephrotoxic ATN (from drugs or pigments). Study the phases: initiation (injury), extension (continued death), maintenance (stable dysfunction), and recovery (regeneration). Understand why dialysis may be needed during maintenance phase.
ATN is not immediately fatal; renal function is maintained despite oliguria through reduced filtration. Most ATN recovers spontaneously with supportive care and fluid management. The muddy brown casts are not diagnostic of ATN specifically; they indicate tubular damage. Not all ischemic AKI is ATN; mild ischemia may cause prerenal azotemia (reversible on fluid administration).
From your study of acute kidney injury, you know that AKI is classified by location: prerenal (reduced perfusion), intrinsic renal (structural damage), and postrenal (obstruction). Acute tubular necrosis (ATN) is the most important cause of intrinsic AKI, accounting for the majority of cases seen in hospitalized patients. Understanding it requires zooming into the tubular epithelial cells — the workhorses of the nephron — and asking what happens when they are deprived of energy or poisoned.
The proximal tubule and thick ascending limb of the loop of Henle are the most vulnerable segments because they have the highest metabolic activity. They rely almost entirely on oxidative phosphorylation to power the ion pumps that reabsorb sodium, glucose, amino acids, and water. When blood flow drops — from sepsis, hemorrhage, or cardiogenic shock — tubular cells lose ATP within minutes. Ion gradients collapse, calcium floods into cells, proteases activate, and cells die by necrosis or apoptosis. This is ischemic ATN. A parallel mechanism underlies nephrotoxic ATN: aminoglycoside antibiotics accumulate in proximal tubule cells (because these cells actively take them up), contrast dye causes transient renal vasoconstriction plus direct tubular toxicity, and myoglobin from crushed muscle precipitates in tubular lumens and generates free radicals. The injury pattern differs slightly by cause, but the result is the same: tubular epithelial death.
The four phases of ATN map onto a logical sequence. The initiation phase is the acute insult itself — hours of ischemia or toxic exposure. The extension phase is continued cell death even after the trigger is removed, driven by reperfusion injury and inflammation. The maintenance phase is a plateau of oliguria lasting days to weeks: surviving tubular cells are alive but dysfunctional, GFR remains depressed, and the patient may require dialysis for fluid and electrolyte management. Finally, the recovery phase is when surviving tubular epithelial cells dedifferentiate, proliferate, and re-epithelialize the damaged segments — a regenerative capacity unique to the kidney and the reason most ATN resolves completely.
The urine sediment is the diagnostic key. Healthy kidneys produce relatively clear urine. ATN produces muddy brown granular casts — these are sloughed tubular epithelial cells and cellular debris that clump together in the tubular lumen. Seeing these casts under microscopy tells you the nephron has sustained direct structural damage, distinguishing ATN from prerenal azotemia (which produces no casts or only hyaline casts). The fractional excretion of sodium (FENa) is also useful: in prerenal AKI, intact tubules avidly reabsorb sodium (FENa < 1%); in ATN, the damaged tubules cannot, so FENa rises above 2%.
The clinical takeaway is probabilistic, not absolute. A hospitalized patient who has been hypotensive for hours, received a nephrotoxic drug, or suffered crush injury who then develops oliguria and rising creatinine almost certainly has ATN. Management is supportive — remove the offending agent, restore hemodynamics, avoid further nephrotoxins — and time. The kidney's regenerative capacity means patience is often rewarded, though patients with baseline CKD or prolonged ischemia have worse recovery trajectories.
No topics depend on this one yet.